Kimia Bioscien.

Why is Kimia Biosciences Ltd falling/rising?

As of 11-Aug, Kimia Biosciences Ltd's stock price is Rs 26.58, down 7.0% and on a downward trend with a total decline of 17.61% over the last six days. The stock has significantly underperformed against the Sensex and is trading below all its moving averages, indicating a bearish trend.

As of 11-Aug, Kimia Biosciences Ltd's stock price is falling, currently at Rs 26.58, reflecting a decrease of Rs 2.0 or 7.0%. The stock has been on a downward trend, having underperformed its sector by 9.51% today and experiencing consecutive losses for the last six days, resulting in a total decline of 17.61% during this period. Additionally, the stock has significantly underperformed against the benchmark Sensex, with a 1-week decline of 14.26% compared to a mere 0.35% drop in the Sensex.<BR><BR>The stock's performance over various time frames also indicates a consistent decline, with a year-to-date drop of 21.71% and a staggering 37.72% decrease over the past year. Furthermore, Kimia Biosciences Ltd is trading below all its moving averages (5-day, 20-day, 50-day, 100-day, and 200-day), which typically signals a bearish trend. <BR><BR>Today's trading session has shown high volatility, with an intraday volatility of 5.47%, and the stock reached a low of Rs 26.1, marking an 8.68% drop at its lowest point. While there has been a rise in investor participation, with delivery volume increasing by 18.16% against the 5-day average, this has not been sufficient to counteract the overall negative sentiment surrounding the stock.

Should I buy, sell or hold Kimia Biosciences Ltd?

Which are the latest news on Kimia Bioscien.?

When is the next results date for Kimia Biosciences Ltd?

The next results date for Kimia Biosciences Ltd is August 10, 2026.

The next results date for Kimia Biosciences Ltd is scheduled for August 10, 2026.

How big is Kimia Bioscien.?

As of 10th June, Kimia Biosciences Ltd has a market capitalization of 157.00 Cr and reported net sales of 114.88 Cr and net profit of 7.43 Cr over the latest four quarters.

As of 10th June, <BR><BR>Market Cap: Kimia Biosciences Ltd has a market capitalization of 157.00 Cr, classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 114.88 Cr, while the sum of Net Profit for the same period is 7.43 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the balance sheet is March 2025. Shareholder's Funds are valued at 9.97 Cr, and Total Assets amount to 109.45 Cr.

Who are in the management team of Kimia Bioscien.?

The management team of Kimia Bioscien includes Sameer Goel (Chairman & Managing Director), Jagdeep Dhavvan (Independent Director), Richa Gupta (Independent Director), Vipul Goel (Director), and Lakshay Prakash (Company Secretary & Compliance Officer).

The management team of Kimia Bioscien includes the following individuals:<BR><BR>1. Sameer Goel - Chairman & Managing Director<BR>2. Jagdeep Dhavvan - Independent Director<BR>3. Richa Gupta - Independent Director<BR>4. Vipul Goel - Director<BR>5. Lakshay Prakash - Company Secretary & Compliance Officer<BR><BR>If you need more details about their roles or the company's activities, feel free to ask!

Who are the peers of the Kimia Bioscien.?

Kimia Bioscien.'s peers include Auro Labs., Achyut Healthcar, Panch.Organics, Parnax Lab, Krebs Biochem, Alpa Laboratorie, Bal Pharma, Accretion Pha., and Quest Laborato. In terms of management risk, Accretion Pha. is rated excellent, while Kimia Bioscien. has below average risk, with a 1-year return of -26.14%.

Peers: The peers of Kimia Bioscien. are Auro Labs., Achyut Healthcar, Panch.Organics, Parnax Lab, Krebs Biochem, Alpa Laboratorie, Bal Pharma, Accretion Pha., and Quest Laborato.<BR><BR>Quality Snapshot: Excellent management risk is observed at Accretion Pha., while Average management risk is found at Auro Labs., Panch.Organics, Alpa Laboratorie, and Bal Pharma, and the rest have Below Average management risk. Growth is Excellent at Accretion Pha., Good at Parnax Lab and Achyut Healthcar, Average at Achyut Healthcar, and Below Average at Auro Labs., Kimia Bioscien., Panch.Organics, Alpa Laboratorie, and Bal Pharma, and the rest. Capital Structure is Excellent at Panch.Organics and Parnax Lab, Good at Accretion Pha., Average at Auro Labs., Alpa Laboratorie, and Bal Pharma, and Below Average at Kimia Bioscien., and the rest.<BR><BR>Return Snapshot: Achyut Healthcar has the highest 1-year return at 71.17%, while Krebs Biochem has the lowest at -29.43%, with Kimia Bioscien.'s 1-year return at -26.14%, indicating it is slightly better than Krebs Biochem. Additionally, the six-month returns are negative for Panch.Organics, Alpa Laboratorie, and Krebs Biochem.

What does Kimia Bioscien. do?

Kimia Biosciences Ltd manufactures Bulk Drugs-APIs in the Pharmaceuticals & Biotechnology industry. As of March 2026, it reported net sales of 27 Cr and a market cap of INR 157 Cr.

Overview:<BR>Kimia Biosciences Ltd is engaged in the manufacturing of Bulk Drugs-APIs and operates within the Pharmaceuticals & Biotechnology industry, categorized as a Micro Cap company.<BR><BR>History:<BR>The company was incorporated in September 1993 and was formerly known as Laurel Organics Limited. It underwent a name change to Kimia Biosciences Limited. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 27 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 0 Cr (Quarterly Results - Mar 2026)<BR>- Market Cap: INR 157 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 21.00<BR>- Industry P/E: 34<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 3.05<BR>- Return on Equity: 64.16%<BR>- Price to Book: 13.48<BR><BR>Contact Details:<BR>- Address: Bhondsi Village, Tehsil Sohna Gurgaon Haryana : 122102<BR>- Tel: 91-11-29535650<BR>- Email: laurelorganicslimited@gmail.com<BR>- Website: http://www.kimiabiosciences.com

Are Kimia Biosciences Ltd latest results good or bad?

The latest results for Kimia Biosciences Ltd are concerning, with Q4 FY26 showing an 81.41% decline in net profit and a 28.87% drop in revenue year-on-year, indicating significant operational challenges and margin compression. Overall, these results are considered bad, raising concerns about the company's financial sustainability.

The latest results for Kimia Biosciences Ltd are concerning. In Q4 FY26, the company reported a net profit of ₹0.37 crore, which represents a staggering decline of 81.41% year-on-year. Revenue also fell significantly, down 28.87% from the previous year to ₹27.20 crore. This decline in revenue was accompanied by a sharp drop in profit margins; the profit after tax (PAT) margin decreased to 1.36% from 5.20% a year ago, and the operating margin fell from 21.39% to 9.82%.<BR><BR>The company's financial performance indicates severe operational challenges, with notable margin compression and a heavy reliance on non-operating income, which accounted for a significant portion of profit before tax. Additionally, the effective tax rate of 78.98% raises questions about the sustainability of the company's earnings.<BR><BR>While the full financial year FY25 showed some improvement with a net profit of ₹9.00 crore and a 13.50% growth in net sales, the recent quarterly performance suggests that this may not reflect a sustainable turnaround. Overall, the latest results can be characterized as bad, highlighting significant risks and operational difficulties for Kimia Biosciences.

Is Kimia Bioscien. overvalued or undervalued?

As of November 17, 2025, Kimia Bioscien. is considered an attractive investment opportunity due to its undervaluation compared to peers, with a PE Ratio of 19.11, a low PEG Ratio of 0.11, and strong ROE of 82.13%, despite a year-to-date stock performance of -27.62%.

As of 17 November 2025, the valuation grade for Kimia Bioscien. has moved from fair to attractive, indicating a positive shift in its market perception. The company is currently considered undervalued, especially when compared to its peers in the pharmaceuticals and biotechnology sector. Key ratios include a PE Ratio of 19.11, an EV to EBITDA of 10.35, and an impressive ROE of 82.13%. <BR><BR>In comparison to its peers, Kimia Bioscien. stands out with a significantly lower PEG Ratio of 0.11, while Sun Pharma. is deemed expensive with a PE Ratio of 36.69 and an EV to EBITDA of 24.22. Other peers like Divi's Lab and Torrent Pharma are also classified as very expensive, with PE Ratios of 69.78 and 59.48, respectively. Despite recent stock performance lagging behind the Sensex, with a year-to-date return of -27.62% compared to the Sensex's 8.72%, the valuation metrics suggest that Kimia Bioscien. presents a compelling investment opportunity at its current price of 33.04.

How has been the historical performance of Kimia Bioscien.?

Kimia Bioscien's historical performance has shown fluctuations, with net sales declining from a peak of 132.71 Cr in Mar'21 to 118.92 Cr in Mar'25. However, the latest fiscal year marked a recovery, with operating profit rising to 21.57 Cr and profit after tax reaching 9.61 Cr, alongside an increase in total assets.

Answer:<BR>The historical performance of Kimia Bioscien shows a fluctuating trend in net sales and profitability over the years, with a notable recovery in the latest fiscal year.<BR><BR>Breakdown:<BR>Kimia Bioscien's net sales peaked at 132.71 Cr in Mar'21 but have since declined, reaching 118.92 Cr in Mar'25. The total operating income followed a similar pattern, with a high of 132.71 Cr in Mar'21 and a decrease to 118.92 Cr in Mar'25. Raw material costs increased to 74.55 Cr in Mar'25 from 67.36 Cr in Mar'24, while total expenditure decreased to 98.67 Cr in Mar'25 from 105.36 Cr in Mar'24. Operating profit (PBDIT) showed a significant recovery, rising to 21.57 Cr in Mar'25 from a loss of 0.48 Cr in Mar'24. Profit before tax also improved to 13.63 Cr in Mar'25, compared to a loss of 7.18 Cr in Mar'24, leading to a profit after tax of 9.61 Cr in Mar'25, a recovery from a loss of 5.31 Cr in the previous year. The company's total assets increased to 109.45 Cr in Mar'25 from 94.18 Cr in Mar'24, while total liabilities also rose to 109.45 Cr from 94.18 Cr, indicating a balanced growth in both assets and liabilities. Overall, Kimia Bioscien has shown a positive turnaround in its financial performance in the latest fiscal year.

Who are the top shareholders of the Kimia Bioscien.?

The top shareholders of Kimia Bioscien include Sameer Goel with 74.94%, individual investors with 23.04%, and Anish Kumar Aggarwal as the highest public shareholder at 4.33%. There are no pledged promoter holdings or foreign institutional investors, and mutual funds hold a minor 0.38%.

The top shareholders of Kimia Bioscien include the promoters, with Sameer Goel holding the highest stake at 74.94%. There are also individual investors who collectively hold 23.04% of the shares. Additionally, Anish Kumar Aggarwal is the highest public shareholder, owning 4.33%. The company has no pledged promoter holdings and is not currently held by any foreign institutional investors. Mutual funds have a minor presence, with three schemes holding a total of 0.38%.

What is the technical trend for Kimia Bioscien.?

As of May 22, 2025, Kimia Bioscien's trend is mildly bearish, influenced by daily moving averages indicating a bearish trend, while weekly indicators show mixed signals, leading to a neutral to mildly bearish outlook.

As of 22 May 2025, the technical trend for Kimia Bioscien has changed from bearish to mildly bearish. The current stance is mildly bearish, primarily driven by the daily moving averages indicating a bearish trend, while the weekly MACD and Bollinger Bands show mildly bullish signals. The weekly RSI remains bearish, suggesting downward pressure, while the monthly indicators present a mixed picture with no strong signals. Overall, the lack of a clear trend in the Dow Theory further supports the neutral to mildly bearish outlook.

Has Kimia Bioscien. declared dividend?

No Dividend History Available